JP2016523956A - 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用 - Google Patents

未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用 Download PDF

Info

Publication number
JP2016523956A
JP2016523956A JP2016524933A JP2016524933A JP2016523956A JP 2016523956 A JP2016523956 A JP 2016523956A JP 2016524933 A JP2016524933 A JP 2016524933A JP 2016524933 A JP2016524933 A JP 2016524933A JP 2016523956 A JP2016523956 A JP 2016523956A
Authority
JP
Japan
Prior art keywords
dose
vegf antagonist
administered
vegf
ranibizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016524933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523956A5 (OSRAM
Inventor
ブリアン，ガブリエラ
アクゼノヴ，セルゲイ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016523956A publication Critical patent/JP2016523956A/ja
Publication of JP2016523956A5 publication Critical patent/JP2016523956A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A61F9/00823—Laser features or special beam parameters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
JP2016524933A 2013-07-11 2014-07-10 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用 Pending JP2016523956A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845073P 2013-07-11 2013-07-11
US61/845,073 2013-07-11
PCT/IB2014/063003 WO2015004626A2 (en) 2013-07-11 2014-07-10 Use of a vegf antagonist in treating retinopathy of prematurity

Publications (2)

Publication Number Publication Date
JP2016523956A true JP2016523956A (ja) 2016-08-12
JP2016523956A5 JP2016523956A5 (OSRAM) 2017-08-17

Family

ID=51211284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524933A Pending JP2016523956A (ja) 2013-07-11 2014-07-10 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用

Country Status (14)

Country Link
US (1) US20160159893A1 (OSRAM)
EP (1) EP3019527A2 (OSRAM)
JP (1) JP2016523956A (OSRAM)
KR (1) KR20160030504A (OSRAM)
CN (1) CN105377890A (OSRAM)
AR (1) AR096893A1 (OSRAM)
AU (3) AU2014288847A1 (OSRAM)
BR (1) BR112016000282A2 (OSRAM)
CA (1) CA2917813A1 (OSRAM)
HK (1) HK1221231A1 (OSRAM)
MX (1) MX2016000385A (OSRAM)
RU (1) RU2676303C2 (OSRAM)
TW (1) TW201536317A (OSRAM)
WO (1) WO2015004626A2 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
MY194736A (en) 2015-09-23 2022-12-15 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
WO2017117512A2 (en) 2015-12-30 2017-07-06 Marshall University Research Corporation Compositions and methods for treating retinopathy
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CA3030298A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.)
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US11253502B2 (en) 2019-04-29 2022-02-22 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the Schlemm's canal
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503828A (ja) * 2002-09-05 2006-02-02 メディミューン，インコーポレイテッド Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
JP2011503064A (ja) * 2007-11-07 2011-01-27 アンスロジェネシス コーポレーション 早産の合併症の治療
JP2012021001A (ja) * 2002-10-24 2012-02-02 Abbott Biotechnology Ltd ＴＮＦα活性が有害である疾患を治療するための低用量方法
JP2012193180A (ja) * 2005-04-15 2012-10-11 Macrogenics Inc 共有結合型ダイアボディとその使用
JP2012525415A (ja) * 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
JP2015526467A (ja) * 2012-08-21 2015-09-10 オプコ ファーマシューティカルズ、エルエルシー リポソーム製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1660057T1 (sl) * 2003-08-27 2012-10-30 Ophthotech Corp Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
EP2349339A4 (en) * 2008-10-16 2015-01-07 Kathleen Cogan Farinas EXTENDED MEDICATION DELIVERY SYSTEM
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"
EP2768504A1 (en) * 2011-10-20 2014-08-27 Avienne Pharmaceuticals GmbH Compositions for controlling vascularization in ophthalmological and dermatological diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503828A (ja) * 2002-09-05 2006-02-02 メディミューン，インコーポレイテッド Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
JP2012021001A (ja) * 2002-10-24 2012-02-02 Abbott Biotechnology Ltd ＴＮＦα活性が有害である疾患を治療するための低用量方法
JP2012193180A (ja) * 2005-04-15 2012-10-11 Macrogenics Inc 共有結合型ダイアボディとその使用
JP2011503064A (ja) * 2007-11-07 2011-01-27 アンスロジェネシス コーポレーション 早産の合併症の治療
JP2012525415A (ja) * 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
JP2015526467A (ja) * 2012-08-21 2015-09-10 オプコ ファーマシューティカルズ、エルエルシー リポソーム製剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOL.THER., vol. 2(3), JPN6018010556, 2012, pages 1 - 22, ISSN: 0004098726 *
CASE REPORTS IN OPHTHALMOLOGY, vol. 3, JPN6018010558, 2012, pages 136 - 141, ISSN: 0004098727 *
TAIWAN JOURNAL OF OPHTHALMOLOGY, vol. 2, JPN6018010554, 2012, pages 136 - 139, ISSN: 0004098725 *

Also Published As

Publication number Publication date
HK1221231A1 (zh) 2017-05-26
KR20160030504A (ko) 2016-03-18
AU2017204326A1 (en) 2017-07-13
RU2016104398A (ru) 2017-08-16
AU2014288847A1 (en) 2016-01-28
WO2015004626A2 (en) 2015-01-15
CA2917813A1 (en) 2015-01-15
RU2676303C2 (ru) 2018-12-27
US20160159893A1 (en) 2016-06-09
CN105377890A (zh) 2016-03-02
RU2016104398A3 (OSRAM) 2018-05-31
TW201536317A (zh) 2015-10-01
AR096893A1 (es) 2016-02-03
WO2015004626A3 (en) 2015-05-28
BR112016000282A2 (pt) 2017-12-12
EP3019527A2 (en) 2016-05-18
AU2019206000A1 (en) 2019-08-01
MX2016000385A (es) 2016-04-29

Similar Documents

Publication Publication Date Title
JP2016523956A (ja) 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用
AU2017203923B2 (en) Use of a VEGF antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
US20250268983A1 (en) Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
JP2016522249A (ja) 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
US11944663B2 (en) Method for treating angiogenic eye disorders using VEGF antagonists
TW201904610A (zh) 用於治療新生血管型青光眼之非抗體vegf拮抗劑
JP2016522248A (ja) ポリープ状脈絡膜血管症の治療
WO2021048806A1 (en) Methods for treating ocular diseases
CN113645994A (zh) 使用色素上皮衍生因子(pedf)治疗疾病的方法
Yuksel et al. Effectiveness of Three Loading Dose of Intravitreal Bevacizumab in Central Diabetic Macular Edema
Stewart New Anti-VEGF Antibody Therapies in Ophthalmology.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190612

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190612

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190625

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190729

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190730

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190823

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190827

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200616

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200721

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20200721

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201117

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201124

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20201222

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20201222